(90)Y-daclizumab, an anti-CD25 monoclonal antibody, provided responses in 50% of patients with relapsed Hodgkin’s lymphoma

Despite significant advances in the treatment of Hodgkin’s lymphoma (HL), a significant proportion of patients will not respond or will subsequently relapse. We identified CD25, the IL-2 receptor alpha subunit, as a favorable target for systemic radioimmunotherapy of HL. The scientific basis for the...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proc Natl Acad Sci U S A
Hauptverfasser: Janik, John E., Morris, John C., O’Mahony, Deirdre, Pittaluga, Stefania, Jaffe, Elaine S., Redon, Christophe E., Bonner, William M., Brechbiel, Martin W., Paik, Chang H., Whatley, Millie, Chen, Clara, Lee, Jae-Ho, Fleisher, Thomas A., Brown, Maggie, White, Jeffrey D., Stewart, Donn M., Fioravanti, Suzanne, Lee, Cathryn C., Goldman, Carolyn K., Bryant, Bonita R., Junghans, Richard P., Carrasquillo, Jorge A., Worthy, Tat’Yana, Corcoran, Erin, Conlon, Kevin C., Waldmann, Thomas A.
Format: Artigo
Sprache:Inglês
Veröffentlicht: National Academy of Sciences 2015
Schlagworte:
Biological Sciences
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4620907/
https://ncbi.nlm.nih.gov/pubmed/26438866
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1516107112
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge